Gilead Sciences, Inc [NASDAQ: GILD] surged by $1.4 during the normal trading session on Wednesday and reaching a high of $112.46 during the day while it closed the day at $112.26.
Gilead Sciences, Inc stock has also loss -2.59% of its value over the past 7 days. However, GILD stock has inclined by 3.94% in the 3 months of the year. Over the past six months meanwhile, it has gained 1.84% and gained 35.56% year-on date.
The market cap for GILD stock reached $139.29 billion, with 1.24 billion shares outstanding and 1.24 billion shares in the current float. Compared to the average trading volume of 6.78M shares, GILD reached a trading volume of 6417189 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Gilead Sciences, Inc [GILD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $126.48 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 1.73. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Daiwa Securities have made an estimate for Gilead Sciences, Inc shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on August 19, 2025. The new note on the price target was released on August 08, 2025, representing the official price target for Gilead Sciences, Inc stock. Previously, the target price had yet another raise to $133, while Needham analysts kept a Buy rating on GILD stock.
The Price to Book ratio for the last quarter was 7.09, with the Price to Cash per share for the same quarter was set at 5.26. Price to Free Cash Flow for GILD in the course of the last twelve months was 14.87 with Quick ratio for the last quarter at 1.15.
GILD stock trade performance evaluation
Gilead Sciences, Inc [GILD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.59. With this latest performance, GILD shares dropped by -4.86% in over the last four-week period, additionally plugging by 1.84% over the last 6 months – not to mention a rise of 21.53% in the past year of trading.
Gilead Sciences, Inc [GILD]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Gilead Sciences, Inc [GILD] shares currently have an operating margin of 38.09% and a Gross Margin at 78.49%. Gilead Sciences, Inc’s Net Margin is presently recorded at 21.91%.
Gilead Sciences, Inc (GILD) Capital Structure & Debt Analysis
According to recent financial data for Gilead Sciences, Inc. ( GILD), the Return on Equity (ROE) stands at 33.26%, highlighting impressive shareholder gains. The Return on Assets (ROA) is 11.55%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Gilead Sciences, Inc’s Return on Invested Capital (ROIC) is 15.09%, showcasing its effectiveness in deploying capital for earnings.
Gilead Sciences, Inc (GILD) Efficiency & Liquidity Metrics
Based on Gilead Sciences, Inc’s (GILD) latest financial statements, the Debt-to-Equity Ratio is 1.27%, indicating its reliance on debt financing relative to shareholder equity.
Gilead Sciences, Inc (GILD) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Gilead Sciences, Inc. (GILD) effectively leverages its workforce, generating an average of $358522.73 per employee. The company’s liquidity position is robust, with a Current Ratio of 1.32% and a Quick Ratio of 1.15%, indicating strong ability to cover short-term liabilities.
Earnings per share (EPS) analysis for Gilead Sciences, Inc [GILD] stock
With the latest financial reports released by the company, Gilead Sciences, Inc posted 2.02/share EPS, while the average EPS was predicted by analysts to be reported at 1.55/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 0.47. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences, Inc go to 26.73%.
Gilead Sciences, Inc [GILD]: Institutional Ownership
There are presently around $90.74%, or 90.83%% of GILD stock, in the hands of institutional investors. The top three institutional holders of GILD stocks are: BLACKROCK INC. with ownership of 120.63 million shares, which is approximately 9.6738%. VANGUARD GROUP INC, holding 115.26 million shares of the stock with an approximate value of $$7.91 billion in GILD stocks shares; and VANGUARD GROUP INC, currently with $$5.23 billion in GILD stock with ownership which is approximately 6.1147%.
